06.02.26 -- Advancing Precision And Scale Across Genetic Medicine

Precision genome editing strategies that balance specificity and potency through engineering workflows, AI‑driven optimization, and tailored editor design for clinical genetic medicines.

Explore how digital solutions help streamline mRNA manufacturing by reducing costs, improving efficiency, and supporting sustainability by creating paperless processes for therapeutics.

Our gene therapy viral vector process development and manufacturing capabilities are designed to confidently and rapidly progress your products from gene to market.

A CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

Silencing cargo gene expression during LVV and AAV production improves cell health, reduces impurities, and significantly increases vector yield for cytotoxic and difficult‑to‑manufacture transgenes.

Rapid cell therapy development demands early planning for scalability, standardized platforms, and inspection‑ready operations to meet rising regulatory expectations and avoid costly rework in later clinical phases.

Advanced F-PERT assays provide the sensitivity needed to identify minute levels of reverse transcriptase activity, ensuring regulatory compliance and rapid safety testing.

Viral vectors are the indispensable backbone of genetic medicine. Learn the fundamental trade-offs and manufacturing strategies for large-scale production of AAV and lentiviral delivery systems.

With 30+ years of experience in viral vector development and manufacturing, we bring unmatched expertise as your trusted CDMO for AAV. From plasmids to fill/finish and advanced analytics, we provide true end-to-end support.